Edgar Filing: Jazz Pharmaceuticals plc - Form 4

Form 4	ceuticals pic											
March 03, 20	4 UNITED	4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									OMB APPROVAL OMB 3235-028 Number:	
Check thi if no long subject to Section 1 Form 4 o Form 5 obligation may cont <i>See</i> Instru 1(b).	6. Filed pu Section 17	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section							burden hou response	Expires: January 31, 2005 Estimated average burden hours per response 0.5		
(Print or Type F	Responses)											
Hooper Suzanne Sawochka Symbol				Issuer Name and Ticker or Trading bol z Pharmaceuticals plc [JAZZ]					5. Relationship of Reporting Person(s) to Issuer			
PLC, CONN	(First) PHARMACEUT VAUGHT HOU TON RD, FL. 4		3. Date of (Month/D 02/27/20	ay/Year)		nsaction			Director X Officer (give below)		b Owner er (specify	
				nendment, Date Original Ionth/Day/Year)					 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
DUBLIN 4,	L2								Form filed by M Person	Aore than One Re	eporting	
(City)	(State)	(Zip)	Tabl	e I - Non	ı-De	erivative S	ecurit	ies Aco	quired, Disposed of	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year	r) Execution any	med on Date, if Day/Year)	Code	etion 3)	n(A) or Dis (D)	sposed	of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Ordinary Shares	02/27/2014			A <u>(1)</u>		10,000	А	\$0	58,682 <u>(2)</u>	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amoun or Numbe of Shar
Nonstatutory Stock Option (right to buy)	\$ 166.62	02/27/2014		А	19,400	(3)	02/26/2024	Ordinary Shares	19,40
Incentive Stock Option (right to buy)	\$ 166.62	02/27/2014		А	600	(3)	02/26/2024	Ordinary Shares	600

Edgar Filing: Jazz Pharmaceuticals plc - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Hooper Suzanne Sawochka C/O JAZZ PHARMACEUTICALS PLC CONNAUGHT HOUSE, 1 BURLINGTON RD, FL. 4 DUBLIN 4, L2			EVP and General Counsel			
Signatures						
/s/ Larissa Schwartz as attorney in fact for Suzanne Saw Hooper	ochka	0	3/03/2014			
<u>**</u> Signature of Reporting Person			Date			
Evelowether of Deensmoore						

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a(1) contingent right to receive one ordinary share upon the vesting of the unit. These units vest in four equal annual installments on the anniversary of the grant date, February 27, 2014.

(2) Includes 349 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 29, 2013.

These two options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these two options vest(3) over four years measured from the grant date, February 27, 2014, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.